Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The impact of cardiovascular diseases on maternal deaths in the Nordic countries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Breech and induction. Time for evidence-based informed consent

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Maternal pre-pregnancy overweight and infertility in sons and daughters: a cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Proteome of fluid from human ovarian small antral follicles reveals insights in folliculogenesis and oocyte maturation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. N-acetylcysteine protects ovarian follicles from ischemia-reperfusion injury in xenotransplanted human ovarian tissue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Serum ferritin level is inversely related to number of previous pregnancy losses in women with recurrent pregnancy loss

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Umbilical cord blood-derived platelet-rich plasma: a clinically acceptable substitute for fetal bovine serum?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

Vis graf over relationer
To enhance oocyte yield and pregnancy outcome in poor responder women undergoing IVF treatment, daily low dose GnRH antagonist administration was given during the late luteal phase to induce luteolysis and possibly secure a more synchronous cohort of recruitable follicles. An open extended pilot study in four Scandinavian fertility centers was done including 60 patients. Poor response was defined as when <or = 5 follicles developed in a preceding cycle following a long agonist protocol with the use of > 2000 IU FSH. GnRH antagonist (ganirelix) was given, 0.25 mg s.c. daily, from days 3 to 5 before expected start of menstruation and continued for 4-7 days. On cycle day 2-3 a starting dose of rFSH (300-400 IU/day) was given. At a leading follicle diameter of 14 mm, ganirelix administration was resumed until final oocyte maturation was induced with 10,000 IU hCG. GnRH antagonist only marginally affected the intercycle FSH rise; basal levels of FSH remained similar to those seen after 4 days of antagonist administration. The protocol effectively induced low LH levels and luteolysis, but daily administration of 350 IU rFSH (median) for 11 days only led to the collection of 3 oocytes in 49 oocyte retrievals resulting in 5 pregnancies (4 delivered). Despite GnRH antagonist administration in the late luteal phase and menstrual bleeding, FSH was not sufficiently reduced to secure a more synchronic cohort of recruitable follicles. Novel GnRH antagonists more specifically targeting FSH release may improve the stimulation results in poor responders.
OriginalsprogEngelsk
TidsskriftActa Obstetricia et Gynecologica Scandinavica
Vol/bind89
Udgave nummer6
Sider (fra-til)828-31
Antal sider4
ISSN0001-6349
DOI
StatusUdgivet - 2010

ID: 32169914